Lung Transplant Rejection Clinical Trial
Official title:
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06309628 -
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
|
||
Withdrawn |
NCT02893176 -
Macitentan in the Treatment of Organ Rejection After Lung Transplantation
|
Phase 4 | |
Completed |
NCT02441413 -
Transplant Optimization Using Functional Imaging (TROFI)
|
N/A | |
Recruiting |
NCT05375149 -
Exhaled Breath Particles in Lung Transplantation
|
||
Active, not recruiting |
NCT03967340 -
PREdiction of Chronic LUng Allograft Dysfunction
|
||
Active, not recruiting |
NCT05260372 -
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
|
||
Recruiting |
NCT06082037 -
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
|
Phase 3 | |
Recruiting |
NCT04714801 -
Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05170425 -
LAMBDA 002 (Lung Registry) Study
|
||
Completed |
NCT02474927 -
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
|
Phase 2 | |
Recruiting |
NCT05006742 -
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
|
N/A | |
Recruiting |
NCT02812290 -
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
|
||
Not yet recruiting |
NCT03500575 -
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
|
N/A | |
Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
Completed |
NCT03359863 -
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
|
Phase 2 | |
Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 | |
Completed |
NCT01985412 -
Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
|
||
Completed |
NCT04234919 -
Longitudinal Study of Cell Free DNA in Lung Transplant
|
||
Recruiting |
NCT03090581 -
Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.
|
N/A | |
Recruiting |
NCT06112951 -
A Prospective Randomized Trial of ECP in Subclinical AMR
|
N/A |